Physician profile
Perini Shah
NPI 1144633819
$3,460.33
in general payments reported to CMS, 2019-2025
31 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $259 · 2021: $454 · 2022: $464 · 2023: $535 · 2024: $617 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $571.54 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $383.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $372.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $288.51 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $223.42 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $223.19 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $222.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $218.96 | 2021-2025 | Qulipta, Ubrelvy |
| Eisai INC. | $118.22 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $115.67 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $109.50 | 2019-2023 | Belsomra |
| Seqirus USA INC | $63.90 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $62.24 | 2024-2025 | |
| Amarin Pharma, INC. | $55.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.45 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $45.82 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $45.11 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $38.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.60 | 2019-2021 | |
| Axsome Therapeutics, INC. | $26.52 | 2025 | Symbravo |
| Allergan, INC. | $24.92 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.35 | 2022 | |
| Organon LLC | $21.10 | 2025 | Nexplanon |
| Becton, Dickinson and Company | $19.37 | 2019 | |
| Itamar Medical INC | $17.48 | 2022 | |
| Tris Pharma INC | $15.67 | 2019 | |
| Sanofi Pasteur INC. | $14.11 | 2019 | |
| Currax Pharmaceuticals LLC | $13.10 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 | |
| Circassia INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perini Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.